PARIS, France, August 2, 2023 – 6:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage Phase 3 biotechnology company developing drugs that modulate the immune system to treat patients with inflammatory diseases chronicles today announces the reset of the conversion/exchange ratio of bonds convertible/exchangeable into new and/or existing shares (OCEANEs) maturing in 2026 for a nominal amount of 24,999,975.99 euros, issued by Abivax SA (ISIN FR0014004PT4).
Holders of OCEANEs are informed by this notice that, pursuant to Article 2.6(D) of the terms and conditions of the OCEANEs and the occurrence of a reset date on July 30, 2023, the conversion/exchange ratio is adjusted from 1.176 to 1.429 with an effective date of July 30, 2023, i.e. a reduction of the implicit conversion/exchange price of the OCEANEs from approximately 32.47 euros per share to approximately 26.72 euros per share. The number of underlying shares thus increases from 769,834 to 935,453 shares.